SOLICITATION NOTICE
B -- Glycomics Analysis
- Notice Date
- 1/10/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2014-049-DLM
- Archive Date
- 1/31/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Children's Hospital of Philadelphia, Room 5NW55, 5th Floor, 34th & Civic Center Boulevard, Philadelphia, Pennsylvania 19104 to perform carbohydrate deficient transferrin analysis by affinity purification and nano-LC-orbitrap analysis to give high-resolution analysis of glycoprotein and corresponding N-glycan analysis changes for NHGRI. Background: The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency seeking fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Institutes of Health Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. Many medical specialties from other NIH research centers and institutes contribute the expertise needed to conduct the program, including endocrinology, immunology, oncology, dermatology, dentistry, cardiology and genetics, among the dozens of participating senior attending physicians. A longstanding medical condition that eludes diagnosis by a referring physician can be considered undiagnosed and may be of interest to this clinical research program. Scope of Work: Provide cutting edge methodology for untargeted detection of pathological changes in the lipid glycosylation, protein-glycosylation and metabolic profiles of plasma, urine, fibroblasts, and/or cultured fibroblast pellets from individuals with neurological disorders. The Children's Hospital of Philadelphia (CHOP) metabolic disease laboratory has developed a number of assays that are much more sensitive than previously available. The laboratory has also taken a lead in the development of assays that are untargeted and can also be used in any body fluid in order that they can be applied to populations with unknown disorders so that new biomarkers can be used to identify novel defects. This technology supports the research needs of the UDP to identify new and rare diseases. The Contractor shall provide the following : • Carbohydrate deficient transferrin analysis by affinity purification and nano-LC-orbitrap analysis. • Untargeted N-glycan analysis in plasma by MALDI-TOF. • Targeted N-glycan analysis of UDP samples that deviate from controls using nano-LC-orbitrap or QTOF. • O-glycan analysis in plasma by MALDI-TOF. • Targeted O-glycan analysis by QTOF for in depth analysis of O-glycan disorders. • Free oligosaccharide analysis in urine by MALDI-TOF with a follow-up by QTOF for in depth analysis. • Glycomics analysis in cultured fibroblasts from patients with abnormalities in blood and urine; o N-glycan and O-glycan profiles of cell pellet will be measured by MALDI-TOF o Oligosaccharides may be measured in the cell pellets and culture media. Specific Tasks : 1. The Contractor shall perform carbohydrate deficient transferrin analysis by affinity purification and nano-LC-orbitrap analysis to give high-resolution analysis of glycoprotein and corresponding N-glycan analysis changes. 2. The Contractor shall perform untargeted N-glycan analysis in UDP patient plasma samples by MALDI-TOF as an initial screen. Further in-depth analysis will be performed on samples containing deviations using an accurate mass analysis by nano-LC-orbitrap or QTOF. 3. The Contractor shall perform untargeted O-glycan analysis on plasma samples using MALDI-TOF and LC-MSMS initially, with follow-up mass analysis screening by QTOF for in-depth screening of O-glycan disorders. 4. The Contractor shall perform free oligosaccharide analysis in urine by MALDI-TOF and in-depth mass screening by QTOF in samples that show deviations from normal samples. 5. The Government will be contacted if any patient results need to be evaluated urgently for impact on caring for patients in the UDP. 6. The Contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system and for exome sequence variant analysis. Justification: The Children's Hospital of Philadelphia (CHOP) Metabolic Laboratory is a CLIA certified laboratory that analyzes approximately 10,000 samples a year for the measurement of targeted and untargeted biomarkers and that can lead to metabolic disease. Additionally, CHOP has been instrumental in working with NHGRI on phase 1 of providing methodology for untargeted detection of pathological changes in the lipid glycosylation, protein-glycosylation and metabolic profiles of cerebrospinal fluid from individuals with neurological disorders from Undiagnosed Disease Samples provided by NHGRI Undiagnosed Disease Program. Period of Performance : March 2014 through March 2015 REGULATORY AUTHORITY: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) and small business size standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-72 (January 1, 2014). This requirement is under the Simplified Acquisition Threshold of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received January 16, 2014 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-049-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2014-049-DLM/listing.html)
- Place of Performance
- Address: Contractor's Location, Philadelphia, Pennsylvania, United States
- Record
- SN03265216-W 20140112/140110235457-364a8a609e5a77f464e7063449710355 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |